Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | BLM | P54132 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | RGS12 | O14924 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrphostin Ag 879 SCHEMBL607702 | 1.00 | MAPT (1.00) | MAPTKMT2AALDH1A1MEN1BLM | |
| Tyrphostin Ag 879 SCHEMBL607701 | 1.00 | MAPT (1.00) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL25736022 | 0.88 | MEN1 (0.78) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL11093690 | 0.86 | EGFR (1.00) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL20333049 | 0.86 | MEN1 (0.76) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL11093692 | 0.86 | EGFR (1.00) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL8346188 | 0.81 | EGFR (0.76) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL6286531 | 0.81 | MAPT (0.68) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL6278934 | 0.81 | MAPT (0.68) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL3244723 | 0.80 | EGFR (0.74) | MAPTKMT2AALDH1A1MEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015066631-A9 | CELL CULTURE MEDIUM AND BIOPROCESS OPTIMIZATION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-07-02 | — | — | WO | claimed |
| WO-2015066631-A2 | CELL CULTURE MEDIUM AND BIOPROCESS OPTIMIZATION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-05-07 | — | — | WO | claimed |
| EP-1482983-A4 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RES DEV CO (IL) | 2006-07-12 | — | — | EP | claimed |
| EP-1482983-A2 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-12-08 | — | — | EP | claimed |
| US-20040197335-A1 | Non-myeloablative tolerogenic treatment with tyrphostins | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2004-10-07 | — | — | US | claimed |
| WO-2003065971-A9 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RES DEV CO (IL) | 2003-11-20 | — | — | WO | claimed |
| WO-2003065971-A2 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-08-14 | — | — | WO | claimed |
| US-6596878-B2 | Protein kinase inhibitor compositio; used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR. | YISSUM RESEARCH & DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY (IL) | 2003-07-22 | — | — | US | claimed |
| US-5981569-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION AND PARTICULARLY KDR/FLK-1 RECEPTOR SIGNAL TRANSDUCTION IN ORDER TO REGULATE AND/OR MODULATE VASCULOGENESIS AND ANGIOGENESIS; TREATMENT OF CANCER, DIABETES, HEMANGIOMA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-11-09 | — | — | US | claimed |
| US-12496341-B2 | Methods for reducing anergy in lymphocytes using modulators of MYC | HTYR ACQUISITION LLC (US) | 2025-12-16 | — | — | US | disclosed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250186400-A1 | SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20250129429-A1 | GENE FUSIONS IN SARCOMA | FOUNDATION MEDICINE, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-12268666-B2 | Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | LOXO ONCOLOGY, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-5849742-A | Compounds for the treament of disorders related to vasculogenesis and/or angiogenesis | SUGEN INC. (US) | 1998-12-15 | — | — | US | disclosed |
| US-5792771-A | FOR TREATING TUMORS, VASCULAR SYSTEM DISORDERS, DIABETES, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS AND HEMANGIOMA | SUGEN, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5763441-A | ADMINISTERING TO THE PATIENT SUFFERING FROM DIABETES, GLIOMA, HEMANGIOMA, KAPOSI'S SARCOMA, OVARIAN/BREAST/PANCREATIC/COLON AND PROSTATE CANCER A BENZO(G)QUINOXALINE COMPOUNDS | SUGEN, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5712395-A | BENZO(G)QUINOXALINE | YISSUM RESEARCH DEVELOPMENT CORP. (IL) | 1998-01-27 | — | — | US | disclosed |
| EP-0748219-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | Sugen, Inc. (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995021613-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186400-A1 | SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | API5, IL5, SRMS | MAPT 867/4885KMT2A 247/4885ALDH1A1 2423/4885 |
| US-12268666-B2 | Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | API5, IL5, SRMS | MAPT 867/4885KMT2A 247/4885ALDH1A1 2423/4885 |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | MAPT 3569/4885KMT2A 562/4885ALDH1A1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.